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ABSTRACT
Despite the high prevalence of co-occurring anxiety in children with autism spectrum
disorder (ASD), little is known about parental preferences for treatment in addressing these
anxiety concerns. Understanding parents’ preferences for treatment is an important factor to
consider for ensuring quality care, as it can guide clinical decisions with regard to
implementation of care, strategies for optimizing engagement and treatment adherence, and is
associated with treatment outcome. To date, limited studies have examined parental preferences
in treatment for childhood anxiety or ASD; but no study has investigated preferences for
treatment in children with comorbid symptoms. Thus, the present study sought to address this
gap in the literature by investigating treatment perceptions and preferences among an adult
sample of parents who have children with ASD and comorbid anxiety. A sample of 46 parents
completed a single-time point, online survey. Parents were presented with the descriptions of
four treatments commonly utilized by families of children with anxiety and ASD: applied
behavior analysis, cognitive-behavioral therapy, medications, and alternative interventions.
Parents were then asked to rate each treatment type in terms of perceived acceptability,
effectiveness, and their willingness to use. Forced-choice items on most and least preferred
treatments to use for their child were also administered. Basic demographic information, child
treatment history and satisfaction, and clinical severity were collected. Results showed that
parents generally perceived all four treatment types as acceptable, effective, and were willing to
use any for their child’s anxiety concerns. A majority of parents ranked medication as the most
preferred treatment for their child, followed by CBT, alternative interventions and ABA. Parental

v

perceptions across treatment types did not differ based on child gender, race/ethnicity or parent
education; differences based on age were only observed for ABA. No associations were found
between parent perception ratings and anxiety or ASD severity. Differences in parent perceptions
across treatment types based on child treatment history showed mixed results. Overall, findings
suggest that parents consider all four treatment types as generally favorable options for
addressing anxiety in their child with ASD. Future studies with larger representative samples are
encouraged to further investigate parent perspectives on treatment, with particular focus on the
factors that drive preferences and the decisions of care.
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INTRODUCTION
Autism Spectrum Disorder (ASD) is a common neurodevelopmental condition,
consisting of two core behavioral characteristics: (1) the presence of persistent deficits in social
communication and interactions; and (2) the presence of excessively repetitive behaviors,
restricted interests, and insistence on sameness (APA, American Psychiatric Association (APA),
2013). In the United States, an estimated 1 in 54 children (~1.8%) meet criteria for an ASD
diagnosis (Maenner, Shaw, & Baio, 2020). Variations by gender and race/ethnicity are observed
for children with ASD. According to a recent report from the Centers for Disease and Control
Prevention (CDC), males are four times as likely to meet criteria for ASD than females (Maenner
et al., 2020). Higher estimated rates of ASD are reported in non-Hispanic white children and
black children compared to Hispanic children (Maenner et al., 2020). Further, although recent
prevalence rates of ASD are similar between non-Hispanic white and black children, disparities
are observed for black children in terms of early identification and intervention (Maenner et al.,
2020).
Notably, the estimated overall prevalence of ASD in the U.S. has considerably increased
over the last couple of decades. In fact, the current prevalence estimate in the U.S. represents a
150% increase over comparable numbers published by the Centers for Disease and Control
Prevention (CDC) in 2000 (Rice et al., 2007). Although the exact reasons for this prevalence
increase remains unclear, several possibilities exist— including the fact that earlier studies on
prevalence relied primarily on clinically-identified samples (White, Oswald, Ollendick, &
Scahill, 2009). With recent advancement in the detection and diagnosis of ASD, more children
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with varying severity are being identified than ever before within the general community. Over
the last several years, diagnostic instruments have improved and can more accurately provide
differential diagnoses across the broad spectrum of autism disorders (White et al., 2009). These
improvements have especially aided in improving differential diagnosis; the detection of ASD
from other overlapping psychiatric disorders in youth (Chakrabarti & Fombonne, 2005).
Nevertheless, with the evident rise in incidence of children diagnosed with ASD and the
economic burden that accompanies this condition (Leigh & Du, 2015), substantial effort is
needed to continue informing and advancing research, as well as to improve access and
utilization of services among the ASD population.
Comorbid psychiatric disorders are common among children and youth with ASD, with
as many as 70% meeting criteria for a co-occurring disorder (Simonoff et al., 2008). Anxiety
disorders are among the most prevalent to co-occur (van Steensel, Bögels, & Perrin, 2011; White
et al., 2009), and an estimated 50-80% of youth with ASD are shown to also have at least
clinically significant symptoms (de Bruin, Ferdinand, Meester, de Nijs, & Verheij, 2007;
Simonoff et al., 2008; Sukhodolsky et al., 2008; van Steensel et al., 2011; White et al., 2009). In
combination with ASD, the presence of an anxiety disorder contributes to significant functional
and life impairment, above and beyond the ASD diagnosis (Kerns et al., 2015). Without adequate
treatment, anxiety symptoms show a worsening trajectory into adolescence and young adulthood,
especially for individuals with ASD (Davis et al., 2011; Kuusikko et al., 2008; Teh, Chan, Tan,
& Magiati, 2017). Youth with ASD and comorbid anxiety have an increased risk for displaying
externalizing behavior problems (Davis et al., 2011), engaging in social avoidance (Davis et al.,
2011; Gillott, Furniss, & Walter, 2001; Klin et al., 2007; Tantam, 2000), and experiencing
difficulties establishing/maintaining relationships with peers, teachers, and family (Drahota,
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Wood, Sze, & Van Dyke, 2011; Higgins, Bailey, & Pearce, 2005; Kim, Szatmari, Bryson,
Streiner, & Wilson, 2000; Rao & Beidel, 2009). In school settings, studies have also shown that
youth with ASD and anxiety present increased disruptive behavior, noncompliance with teacher
demands, and disengagement from peer-centered activities (Bauminger & Kasari, 2000;
Chamberlain, Kasari, & Rotheram-Fuller, 2007; Lounds, Seltzer, Greenberg, & Shattuck, 2007;
Matson & Smith, 2008). With the ever-growing prevalence of comorbid anxiety disorders among
youth with ASD, it has become increasingly evident that anxiety should be a key focus when
treating these youth on the spectrum.
Studies have shown meaningful evidence to suggest that cognitive behavioral therapy
(CBT) is effective for treating anxiety in children and adolescents with ASD (Drahota et al.,
2011; Ehrenreich-May et al., 2014; Storch et al., 2013; Storch et al., 2015; Wood et al., 2015).
CBT is considered the first-line treatment for individuals with anxiety disorders (Reynolds,
Wilson, Austin, & Hooper, 2012). It is a short-term, skills-focused intervention, where
individuals learn to address maladaptive emotional responses to distressing or feared
conditions/situations (Kaczkurkin & Foa, 2015). For youth with ASD and anxiety, modifying
traditional CBT to better-fit developmental needs has become an increasingly common treatment
option. In fact, several studies have provided evidence on the efficacy and utility of a modified
CBT protocol for reducing anxiety symptomology in youth with ASD (Drahota et al., 2011;
Storch et al., 2013; Storch et al., 2015; Wood et al., 2015; Wood et al., 2020).
There are several pharmacological options available for treating anxiety in youth with or
without ASD, as well. The most common choice is the use of selective serotonin reuptake
inhibiters (SSRIs), which has been shown to be efficacious in both adults and children with
anxiety, OCD and depression (Nadeau et al., 2011). It is suggested that SSRIs may have a utility

3

in regulating the dysfunctional serotonin activity that is associated with the compulsive behaviors
and anxiety present in individuals with ASD (Leskovec, Rowles, & Findling, 2008); although,
precise evidence has not yet been established. Several randomized controlled trials (RCTs) have
also been conducted that present preliminary efficacy in the use of SSRIs— such as fluoxetine,
sertraline, citalopram— for reducing ASD and related symptoms (e.g., anxiety,
compulsive/repetitive behaviors; Couturier & Nicolson, 2002; Hollander et al., 2005; McDougle
et al., 1998; Namerow, Thomas, Bostic, Prince, & Monuteaux, 2003).
With parents at the forefront of addressing their children’s needs, it is important to take
into account parental preferences for treatment. Parents serve as the primary gateway for children
accessing needed services. Youth are often dependent on their parent and/or primary caregiver(s)
to recognize problems in their physical, emotional, and/or mental state. Likewise, children are
often dependent on their caregiver(s) to recognize when there is need to seek help and access the
appropriate care. To that end, parental preferences for available treatments overall play a critical
role in the utilization of services.
Parents will often have specific preferences for use of some treatments over others. These
preferences will be associated with the individual’s perceptions and experiences regarding
treatment. For example, preferences may stem from how well a given treatment aligns with the
family’s collective beliefs/values or be influenced by the practical facilitators/barriers (e.g., cost,
accessibility) associated with treatment. Other factors such as stigma, perceived risks and
benefits (or effectiveness), or perceived acceptability of treatment may also play key components
in establishing preference and the willingness to use one treatment over another. Notably, child
(or patient) characteristics may also influence preferences for treatment— for instance, age,
race/ethnicity, culture, temperament, and/or the severity of illness.
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Assessing preferences for treatment can have positive implications for an individual’s
care. For parents of children with ASD and comorbid anxiety, their preferences may not only
influence the type of treatment chosen for their child’s needs, but also have an effect on the way
that family adheres to treatment. Several depression studies on patient preference have shown
that treatment adherence (even outcome) improved among those who received their preferred
choice of care (e.g., medications and/or psychotherapy; Dunlop et al., 2017; Kocsis et al., 2009;
Lin et al., 2005; Raue, Schulberg, Heo, Klimstra, & Bruce, 2009). Understanding preferences for
treatment can also aid in the way providers assist families in making informed choices about
care. When it comes to ASD-focused interventions, parents are faced with a variety of different
choices— for example, applied behavioral analysis (ABA), social skills training, psychotherapy
(such as CBT), speech, occupational and physical therapy, medications, as well as some
alternative approaches to conventional treatment (e.g., elimination diets, nutritional supplements,
yoga; Brondino et al., 2015; Mackintosh, Goin-Kochel, & Myers, 2012). Yet, too often parents
are left without adequate information to make an informed therapeutic decision on what is best
for their child’s care. Parents will often enroll their child with ASD into multiple treatments and
services simultaneously, to increase their child’s chances of finding a “best-fit” intervention
(Mackintosh et al., 2012). Although it is evident that parents of children with ASD will utilize
many services over the child’s lifetime, little is known about parents’ satisfaction or perceptions
with available treatments or their preferences overall.
In general, assessing patients’ treatment preferences has been shown to result in better
outcomes for patients, providers, and the health care system (Mulley, Trimble, & Elwyn, 2012).
With regard to anxiety and related disorders, only a handful of studies have examined treatment
preferences among individuals and parents (Brown, Deacon, Abramowitz, Dammann, &
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Whiteside, 2007; Deacon & Abramowitz, 2005; Lewin, McGuire, Murphy, & Storch, 2014;
Patel, Galfavy, Kimeldorf, Dixon, & Simpson, 2016; Patel & Simpson, 2010). In ASD, limited
studies have been conducted¾ most of which have examined treatment perceptions and
utilization of ASD-focused services, but not overall preference (Goin-Kochel, Mackintosh, &
Myers, 2009; Goin-Kochel, Myers, & Mackintosh, 2007; Mackintosh et al., 2012). Findings
from these past studies suggest that both parents and individuals tend have a more favorable
perception of behaviorally-focused treatments for anxiety or ASD over common
pharmacological approaches or alternative interventions (e.g., elimination diets, nutritional
supplements). Several factors also emerged that may be associated with treatment preferences,
including the child’s age and child’s previous history of treatment-use (Brown et al., 2007; GoinKochel et al., 2009; Mackintosh et al., 2012). The symptom severity of the condition did not
appear to influence preference across studies; however, additional investigations on this potential
factor is warranted, as illness severity will likely have influence in the clinical recommendations
of care.
Overall, previous studies have investigated parents’ preferences for various ASD or
anxiety interventions; yet to date, there are no studies that have examined treatment preferences
among parents of children with ASD and comorbid anxiety. Considering the high prevalence of
anxiety disorders in children with ASD, and the significant impact anxiety symptoms can have
on a child (i.e., above and beyond an ASD diagnosis), assessing parental preferences toward
specific treatments for both conditions are warranted. Understanding these preferences for
treatment of individuals with ASD and anxiety— as well as the potential factors that may
influence the perceptions of treatment— are critical for improving the quality and outcomes of
care. By addressing this gap in literature, providers will have the opportunity to develop
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informed strategies for optimizing family engagement and improving adherence with treatment
recommendations for this specific population (Patel et al., 2016). Thus, the present study sought
to investigate the parental preferences of treatment for anxiety in children with ASD.

Aims of the Current Study
The overall purpose of the current study was to examine treatment preferences for
anxiety, among an adult sample of parents, who have children with ASD and co-occurring
anxiety. Specifically, the study had two aims:
Aim 1. To examine parental perceptions of and preference for the treatment of anxiety in
children with ASD.
Hypothesis 1. Consistent with previous literature (e.g., Brown et al., 2007; Lewin et al.,
2014), it was hypothesized that parents would perceive behavioral interventions (ABA,
CBT) as more favorably (acceptability, effectiveness, and willingness to use) compared
to medications or alternative interventions.
Aim 2. To explore potential relationships of demographic and clinical factors with parental
perceptions of medication-based anxiety treatments.
Hypothesis 2. Consistent with previous literature (e.g., Brown et al., 2007; Goin-Kochel
et al., 2007), it was hypothesized that parents of older children would perceive
medications more favorably (in acceptability, effectiveness, and willingness to use),
compared to parents of younger children.
Hypothesis 3. It was hypothesized that higher anxiety severity would be associated with
higher perceived favorability (in acceptability, effectiveness, and willingness to use) for
medication.
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Hypothesis 4. It was hypothesized that parents whose child had a history of medication
use would also be more likely to perceive medications favorably, relative to those who
had not.
Exploratory Aim 3. There is insufficient evidence regarding factors associated with parent
perceptions of other types of non-medication treatments for child anxiety in youth with ASD.
Thus, an exploratory aim was to explore potential relationships of demographic and clinical
factors with parental perceptions of non-medication anxiety treatments
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METHODS
Participants
Participants included a community sample of parents with at least one child (of any age)
with ASD and significant anxiety. In addition, parents met the following eligibility criteria: a)
aged 18 years and over, and b) able to read/understand English. A total of 79 participants
consented and completed at least part of the survey; 24 (30.3%) participants were excluded from
analyses as they did not complete any of the perceptions of anxiety treatment scale items and 9
(11.4%) were excluded for missing responses within the scale. Thus, the final sample consisted
of 46 parents, who ranged in age from 27 to 68 years (M = 45.0; SD = 8.2). Overall, parents were
predominantly female (95.7%), white (82.6%) non-Hispanic/Latino (87.0%) and highly
educated. A majority of parents also reported a total household income above $80,000. Their
children ranged in age from 2 to 25 years (M = 12.5; SD = 5.1), and were predominately male
with moderate reported ASD severity, as well as moderate-to-severe reported anxiety severity.
Details regarding sample demographic and clinical characteristics are reported in Table 1.
Procedures
The study was approved by the Baylor College of Medicine Institutional Review Board
(IRB; protocol H-43121). Participants were primarily recruited through circulation of the
approved advertisement flyer across various sources: online ASD forums (e.g., parent support
groups, community organization pages), Texas and Florida-based autism centers, and via email
to families participating in a local autism center research database. The advertisement included a
web-link to the anonymous online Qualtrics survey, which potential participants were invited to
9

complete. Prior to initiating the online survey, participants were presented with the IRBapproved consent document. Thereafter, participants were administered the measures of the
online survey. Participation was voluntary, responses were collected anonymously, and no
compensation was provided. Data were collected from January-May 2020.
Measures
Demographics and History Questionnaire. Parents were asked to provide demographic
information about themselves: age, gender, race/ethnicity, highest level of education, and
income. Parents also provided basic demographic information about their child with ASD and
anxiety (i.e., age, gender, and race/ethnicity). A list of common treatments/services for ASD and
anxiety were then presented to the parent and they were asked to respond yes/no to ever utilizing
any for their child’s needs. Ratings of parent satisfaction for the treatments/services utilized were
also collected, using a 5-point scale (very dissatisfied, dissatisfied, neither, satisfied, very
satisfied).
Perceptions of Anxiety Treatment Scale (PATS). The PATS was developed to assess
parents’ perceptions of and preferences for treatment of anxiety in children with ASD (see full
measure in Appendix A). The questionnaire describes four treatment approaches for anxiety:
applied behavior analysis, cognitive-behavioral therapy, medications, and alternative
interventions. For each, a brief description of the treatment approach, the recommended duration
and typical cost of treatment, as well as the potential advantages and disadvantages of treatment
were presented. Parents were asked to read each treatment description and then rate their
perceived acceptability, effectiveness, and willingness to use each type for their own child’s
anxiety. Ratings were captured using an 11-point Likert scale, from 0 (not at all acceptable,
effective, or willing) to 10 (completely acceptable, effective, or willing). Parents were also asked
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to rate, from 0 (not at all) to 10 (completely), the extent to which the following factors influenced
their perceptions about each treatment: personal experience, the expected cost/coverage of
treatment, the availability of treatment, their child’s engagement with treatment, their overall
understanding of that treatment, and other practical barriers for accessing that treatment. Finally,
parents were presented with a forced-choice question, in which they were asked to rank each of
the four treatment types from most-preferred treatment for their child (a ranking of 1) to leastpreferred treatment for their child (a ranking of 4). The presentation of each treatment
description was modeled from the Treatment Perceptions Questionnaire-Parent Version (TPQ-P;
Brown et al., 2007; Deacon & Abramowitz, 2005); however, content for all was original, based
on existing literature, and reviewed by experts in the field. Consistent with the TPQ-P, treatment
descriptions were similar in content, length, and format. The descriptions were also presented to
parents in random order to reduce order effects (Brown et al., 2007). In this study, acceptability,
effectiveness, and willingness were selected as “perception” constructs based on previous
literature and their use in past preference studies (Brown et al., 2007; Croghan et al., 2003;
Deacon & Abramowitz, 2005; Patel et al., 2016).
Spence Children’s Anxiety Scale - Parent Form (SCAS-P; Nauta et al., 2004; Spence,
1999). The SCAS-P is a 38-item parent report measure designed to assess anxiety symptoms in
youth. Responses were rated on a 4-point Likert scale, ranging from 0 (Never) to 3 (Always).
Item responses were summed to yield a total score, with higher scores corresponding to greater
anxiety severity. Six anxiety subscales were also calculated: separation, social, generalized,
physical injury fears, panic attacks/agoraphobia, and obsessive-compulsive. The SCAS-P
demonstrates good psychometric properties with regard to internal consistency, reliability, and
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validity in youth with and without ASD (Magiati et al., 2017; Muris, Merckelbach, Ollendick,
King, & Bogie, 2002; Muris, Schmidt, & Merckelbach, 2000; Spence, 1998).
Clinical Global Impression Scale – Severity (CGI-S; Guy, 1976). The CGI-S is widely
used in clinical samples to assess global illness severity and is typically rated by a
clinician/professional (Guy, 1976). For purposes of the study, the CGI-S was adapted to capture
parent-report ASD and anxiety severity. Parents were asked to describe their child’s
symptoms/functioning using a 7-point Likert scale, ranging from 0 (No illness) to 6 (Extremely
severe symptoms).
Data Analytic Plan
Data were analyzed using SPSS version 24. Descriptive statistics were computed to
describe demographics of parents and children, clinical characteristics of children, and utilization
of treatments/services for addressing child's anxiety and/or ASD concerns (see Table 1). Given
the present sample size (n <50), the Shapiro-Wilk test of normality were computed to examine
the distribution of sample data. Assessment of distribution revealed that the data were not
normally distributed (p < .05). Thus, non-parametric tests were used to analyze data, where
appropriate. Owning to the relatively small size of the present sample, demographic variables
with multiple groups were redistributed to fit two groups for analyses, in order to increase the
number of individuals included in each category. Specifically, child’s race and ethnicity were
recoded to fit a ‘minority’ group (inclusive of those who identified as Hispanic white, Black,
Asian, Native Hawaiian/Pacific Islander, and Bi-racial/Mixed race; n=18) and a ‘non-minority’
group (inclusive of those who identified as non-Hispanic white; n=28). Parent’s education was
also recoded to fit a ‘degree’ group (inclusive of those with an associate’s, bachelor’s or
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postgraduate degree; n=34) and a ‘no degree’ group (inclusive of those with a high school
diploma/GED, some college but no degree, a trade/technical training, or other [A levels]; n=12).
To test the first study aim, the two types of analyses were conducted. First, descriptive
statistics were used to assess parental rankings of preferred treatment for anxiety in children with
ASD, as well as parental ratings of acceptability, effectiveness, and willingness-to-use across the
four treatment types. Second, Friedman's tests were performed to determine whether there were
overall differences in parent perception ratings (i.e., acceptability, effectiveness, and willingness)
across the four treatment types. If a significant difference was found across the four treatment
types, post hoc pairwise comparisons were further performed to determine where the exact
difference existed between treatment groups. Due to the many planned analyses and the fact that
the study included exploratory aims, it was considered whether the Bonferroni correction for
multiple comparisons would be appropriate to apply to the post hoc tests, in order to control for
increased risk of Type I error. Following recommendations from Armstrong (2014), a Bonferroni
correction for multiple comparisons should be considered if: (a) testing the ‘universal null
hypothesis’ is required to examine whether all tests are not significant; (b) it is critical to reduce
the likelihood of type I error; and (c) mass testing is needed in an attempt to determine if any
results may be significant, in absence of any preplanned hypotheses. None of the planned
analyses of this study met all three criteria. As such, it was decided that a Bonferroni correction
for multiple comparisons would not be applied to any post hoc comparisons from Friedman’s
tests. Kendall’s Coefficient of Concordance (W) was calculated to examine effect size (Green &
Salkind, 2008) and was interpreted using the following metric: very weak effect (< .20), weak
effect (.20 to .39), moderate effect (.40 to .59), strong effect (.60 to .79), and very strong effect
(.80 to 1.00) (Rovai, Baker, & Ponton, 2013). Together, these set of analyses addressed the first

13

hypothesis, that parents would perceive the behavioral interventions (ABA and CBT) favorably
(in terms of acceptability, effectiveness, and willingness-to-use) compared to medication or
alternative interventions.
To test the second aim and the exploratory aim, several analyses were conducted. A
series of Mann-Whitney U tests were conducted to determine if parent perception ratings
(acceptability, effectiveness, willingness) were associated with the following demographic
variables: the child’s gender (male vs. female), child’s age group (≤12 years old vs. ≥13 years
old), child’s race/ethnicity (minority vs. non-minority group), and parent’s education (degree vs.
no degree). Spearman’s correlations were conducted to examine whether treatment perception
scores were associated with anxiety or ASD severity. Finally, Mann-Whitney U tests were also
conducted to examine whether parent perception ratings were associated with a previous history
of each treatment type (ABA, CBT, medication, alternative intervention). Together, these
analyses tested the hypotheses of aim two, which asserted that parents would perceive
medications more favorably based on age group, anxiety severity, and previous treatment
history, as well as exploring the constructs in exploratory aim 1.
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Table 1. Sample demographic and clinical characteristics (N=46)
Demographic Characteristic
Variable

Category

Age

12 years and younger

Parent

Child

n (%)

n (%)

-

25 (54.3)

13 years and older

46 (100.0)

21 (45.7)

Gender

Female
Male

44 (95.7)
2 (4.3)

10 (21.7)
36 (78.3)

Ethnicity

Hispanic/Latino

6 (13.0)

9 (80.4)

Not Hispanic/Latino

40 (87.0)

37 (19.6)

White
Black or African American

38 (82.6)
3 (6.5)

35 (76.1)
3 (6.5)

Asian

3 (6.5)

3 (6.5)

Native Hawaiian/Pacific Islander
Bi-racial/Mixed Race

1 (2.2)
1 (2.2)

1 (2.2)
4 (8.7)

High School Diploma/GED

2 (4.3)

-

Some College/No Degree
Trade/Technical Training

6 (13.0)
3 (6.5)

-

Associate Degree

4 (8.7)

-

Bachelor’s Degree

16 (34.8)

-

Postgraduate Degree
Other

14 (30.4)
1 (2.2)

-

$0 – $9,999

0 (0.0)

-

$10,000 – $19,999
$20,000 – $29,999

1 (2.2)
3 (6.7)

-

$30,000 – $39,999

5 (11.1)

-

$40,000 – $49,999

4 (8.9)

-

$50,000 – $59,999
$60,000 – $69,999

1 (2.2)
4 (8.7)

-

$70,000 – $79,999

1 (2.2)

-

$80,000 and Over

26 (57.8)

-

Parent

Child

Racial Background

Highest Education

Household Income

Clinical Characteristics
Variable

Category

n (%)

n (%)

CGI-S ASD

No illness

-

0 (0.0)

Illness slight

-

0 (0.0)

Mild symptoms

-

14 (30.4)

Moderate symptoms

-

26 (56.5)

Moderate-Severe symptoms

-

4 (8.7)

Severe symptoms

-

2 (4.3)

Extremely severe symptoms
No illness

-

0 (0.0)
0 (0.0)

Illness slight

-

0 (0.0)

Mild symptoms

-

1 (2.2)

CGI-S Anxiety
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Table 1 (continued). Sample demographic and clinical characteristics
Clinical Characteristics

Parent

Child

n (%)

n (%)

Variable

Category

CGI-S Anxiety

Moderate symptoms

-

9 (19.6)

Moderate-Severe symptoms

-

13 (28.3)

Severe symptoms

-

10 (21.7)

Extremely severe symptoms

-

11 (23.9)

-

38.8 (17.0)a

Yes

-

23 (50.0)

No

-

23 (50.0)

Yes

-

19 (41.3)

No

-

27 (58.7)

Yes

-

28 (60.9)

SCAS-P Total Score
Used Applied Behavioral Analysis
Used Cognitive-Behavioral Therapy
Used Medication

No

-

18 (39.1)

Used Social Skills Training

Yes

-

24 (52.2)

Used Speech Therapy

No
Yes

-

22 (47.8)
33 (71.7)

No

-

13 (28.3)

Used Occupational Therapy

Yes

-

37 (80.4)

Used Parent-Child Interaction Therapy

No
Yes

-

9 (19.6)
6 (13.0)

No

-

40 (87.0)

Used Play Therapy

Yes
No

-

15 (32.6)
31 (67.4)

Used Specialized Diet

Yes

-

23 (50.0)

No

-

23 (50.0)

Yes
No

-

39 (84.8)
7 (15.2)

Used Specialized School Services

Note. a Means and standard deviations were reported for continuous variables; CGI-S=Clinical Global Impression–Severity;
ASD=Autism Spectrum Disorder; SCAS-P=Spence Children Anxiety Scale–Parent report.
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RESULTS
Assessing Parent Perceptions of Treatment
Acceptability of Treatments. Figure 1 displays parent acceptability ratings across each of
the four treatment types. Friedman's nonparametric test indicated that ranked acceptability
ratings were significantly associated with treatment type: χ2(3) = 9.27, p = .03; W = .07. Table 2
presents post hoc pairwise comparisons, performed to determine how treatment acceptability
ratings differed by treatment type. Post hoc analyses revealed that ranked acceptability ratings
were significantly higher for CBT compared to medication (p = .014).
Effectiveness of Treatments. Parent effectiveness ratings for each treatment type are
shown in Figure 2. Friedman’s test indicated that effectiveness ratings were not significantly
associated with treatment type: χ2(3) = 5.33, p = .15; W = .04.
Willingness-to-Use Treatments. Figure 3 displays parent willingness ratings for each
treatment type. Friedman's nonparametric test indicated that acceptability ratings were
significantly associated with treatment type: χ2(3) = 10.27, p = .02; W = .07. Table 3 presents
post hoc pairwise comparisons, performed to determine whether treatment willingness ratings
differed by treatment type. Post hoc analyses revealed that ranked willingness ratings were
significantly higher for CBT compared to medication (p = .043). Ranked willingness ratings
were also significantly higher for CBT compared to ABA (p = .009).
Factors Influencing Perceptions of Treatments. The degree to which six factors (i.e.,
personal experience, cost/coverage, availability, child engagement, overall understanding and
other practical barriers) influenced parent perceptions toward each of the four treatment types are
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shown in Figures 4-7. More than 60% of parents indicated that each of the six factors at least
‘moderately’ influenced their perceptions about ABA and CBT. For both treatment types, the
parent’s own understanding of the treatment was rated most frequently among parents for
‘completely’ influencing their perceptions about treatment (46% and 37% for ABA and CBT,
respectively), compared to other factors. More than 50% of parents indicated that their
perceptions about medications were influenced at least ‘moderately’ by each of the presented
factors, with the exception of practical barriers (which was rated at least moderately by <50%).
Personal experience was rated most frequently by parents for ‘completely’ influencing their
perceptions about medication (54%), followed by the parents’ own understanding of treatment
(33%). Finally, more than 50% of parents indicated that each of the six factors at least
‘moderately’ influenced their perceptions about alternative interventions. The parent’s own
understanding of the treatment was also rated most frequently among parents for ‘completely’
influencing their perceptions about alternative interventions (33%) compared to other factors.
Assessing Parent Preferences for Treatment
Parent rankings of preference for each of the four presented treatment types are shown in
Figure 8. Of the present sample, medication was endorsed by parents most (n= 16) as the ‘most
preferred’ treatment above the other three types. CBT was endorsed most as the second preferred
treatment (n=15), and alternative interventions was endorsed most as the third preferred
treatment (n=17). Finally, ABA was endorsed by parents most as the ‘least preferred’ treatment
(n=17), above the other three types.
Differences in Parent Perceptions based on Demographic Factors
Child’s Gender. Differences in parent perception ratings between male and female
children are reported in Table 4. Mann-Whitney U tests revealed that parent perception ratings
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did not significantly differ between male and female children for any of the four treatment types
(all ps > .05).
Child’s Age. Differences in parent perception ratings between younger children (aged ≤
12 years) and older children (aged ≥ 13 years) are presented in Table 5. Mann-Whitney U tests
revealed significant differences between the two age groups for ABA acceptability,
effectiveness, and willingness ratings (all ps < .05). All three perception ratings for ABA were
significantly higher for younger children than for older children. Group differences between age
groups were not significant for CBT, medication, or alternative intervention perception ratings.
Child’s Race/Ethnicity. Differences in parent perception ratings between minority
children and non-minority children are shown in Table 6. Mann-Whitney U tests indicated that
parent perception ratings did not significantly differ between minority and non-minority children
for any of the four treatment types (all ps > .05).
Parent’s Education. Differences in parent perception ratings between parents with a
degree and parents without a degree are reported in Table 7. Mann-Whitney U tests indicated
that parent perception ratings did not significantly differ between parents with a degree and
parents without a degree for any of the four treatment types (all ps > .05).
Associations between Parent Perceptions and Child Clinical Characteristics
The associations between parent perception ratings across treatment types and clinical
variables are presented in Table 8. Spearman’s ranked-order correlations revealed no significant
associations of parent perception ratings to child anxiety severity or ASD severity. In general,
ratings of acceptability, effectiveness, and willingness were moderately to strongly positively
correlated within the same treatment type, but not across treatment types. The exceptions were
significant weak positive correlations between; i) ABA willingness and CBT acceptability
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ratings, ii) ABA willingness and CBT effectiveness ratings, and iii) medication acceptability and
CBT willingness.
Parent Perceptions based on Child Treatment History
Figure 9 presents parent-reported satisfaction with past treatments/services utilized for
their child’s needs. At least 50% of parents who had used any of the listed treatment/services
reported satisfaction for all except medication and specialized diets; only 47% and 26% reported
satisfaction with medication and specialized diets, respectively. Dissatisfaction towards
treatments were also fairly low (<20%) for all except CBT and specialized diets.
Differences in parent perception ratings between children with a previous history of each
treatment type and those without a history are presented in Table 9. Mann-Whitney U tests
revealed that all three perception ratings for ABA were significantly higher for children with a
history of using ABA compared to those who had not. All three perception ratings for medication
were also significantly higher for children with a history of medication-use compared to those
without previous medication use. For alternative interventions, parent effectiveness ratings were
significantly higher for children with a history of using specialized diets compared to those
without a history; but no group differences were found in acceptability or willingness ratings
based on previous use of specialized diets. There were also no significant group differences
found between those with a history of CBT and those without for any of the CBT perception
ratings.
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Table 2. Pairwise comparisons of parent acceptability ratings by treatment type
Sample 1–Sample 2

Friedman’s test statistic

Pairwise test statistic

Significance

ABA – CBT
-.500
-1.857
.063
Medication – Alt. Intervention
-.453
-1.615
.106
ABA – Alt. Intervention
-.272
-1.009
.313
Medication – ABA
.163
.606
.545
Alt. Intervention – CBT
.228
.848
.396
Medication – CBT
.663
2.463
.014*
*p =.05
Abbreviations: ABA, applied behavioral analysis; CBT, cognitive-behavioral therapy; Alt. intervention, alternative interventions.

Table 3. Pairwise comparisons of parent willingness ratings by treatment type
Sample 1–Sample 2

Friedman’s test statistic

Pairwise test statistic

Significance

ABA – CBT

-.707

-2.625

.009**

Medication – Alt. Intervention

-.272

-1.009

.313

ABA – Alt. Intervention

-.435

-1.615

.106

Medication – ABA

-.163

-.606

.545

Alt. Intervention – CBT

.272

1.009

.313

Medication – CBT
.543
2.019
.043*
*p =.05 **p =.01
Abbreviations: ABA, applied behavioral analysis; CBT, cognitive-behavioral therapy; Alt. intervention, alternative interventions.

Table 4. Differences in parent perception ratings based on child’s gender
Male
(n = 36)

Female
(n = 10)

Mann-Whitney U Test

Median

Median

U

z

p

Treatment Type

Perception Type

ABA

Acceptability

5.50

8.00

179.0

-0.027

.990

Effectiveness

5.00

5.00

173.0

-0.189

.865

Willingness

5.00

6.50

192.5

0.338

.743

Acceptability

7.50

10.00

216.5

1.038

.336

Effectiveness

5.00

6.50

219.0

1.061

.310

Willingness

8.00

10.00

237.5

1.615

.127

Acceptability

5.00

6.50

205.0

0.677

.520

Effectiveness

5.00

6.00

202.5

0.605

.555

Willingness

5.00

6.50

159.5

-0.564

.591

Acceptability

5.50

10.00

250.5

1.956

.060

Effectiveness

5.00

6.00

206.5

0.734

.486

Willingness

7.00

8.50

235.0

1.492

.149

CBT

Medication

Alternative Interventions

*p ≤ .05; Abbreviations: ABA, applied behavioral analysis; CBT, cognitive-behavioral therapy.
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Table 5. Differences in parent perception ratings based on child’s age
≤12 years
(n = 25)

≥13 years
(n = 21)

Mann-Whitney U Test

Median

Median

U

z

p

Treatment Type

Perception Type

ABA

Acceptability

8.00

5.00

158.0

-2.369

.018*

Effectiveness

5.00

4.00

148.5

-2.551

.011*

Willingness

7.00

4.00

156.0

-2.387

.017*

Acceptability

10.00

7.00

181.5

-1.908

.056

Effectiveness

5.00

5.00

239.0

-0.529

.596

Willingness

8.00

9.00

248.5

-0.326

.745

Acceptability

5.00

5.00

257.5

-0.112

.911

Effectiveness

7.00

5.00

288.5

0.579

.562

Willingness

5.00

5.00

268.5

0.137

.891

Acceptability

7.00

7.00

274.0

0.264

.792

Effectiveness

5.00

5.00

279.5

0.390

.697

Willingness

8.00

7.00

269.5

0.157

.875

CBT

Medication

Alternative Interventions

*p ≤ .05; Abbreviations: ABA, applied behavioral analysis; CBT, cognitive-behavioral therapy.

Table 6. Differences in parent perception ratings based on child’s race/ethnicity
Minority
(n = 18)

Non-Minority
(n = 28)

Mann-Whitney U Test

Median

Median

U

z

p

Treatment Type

Perception Type

ABA

Acceptability

9.00

5.00

175.5

-1.770

.077

Effectiveness

5.00

5.00

243.5

-0.194

.846

Willingness

6.00

5.00

212.5

-0.903

.366

Acceptability

7.50

9.50

287.0

0.842

.400

Effectiveness

5.00

5.50

257.0

0.115

.908

Willingness

5.00

9.50

314.5

1.483

.138

Acceptability

5.00

5.00

286.5

0.790

.429

Effectiveness

5.00

5.00

272.5

0.466

.641

Willingness

5.00

6.50

289.0

0.861

.389

Acceptability

8.00

5.50

208.5

-1.020

.308

Effectiveness

5.00

5.00

252.0

0.000

1.00

Willingness

7.50

7.00

265.0

0.298

.766

CBT

Medication

Alternative Interventions

*p ≤ .05; Abbreviations: ABA, applied behavioral analysis; CBT, cognitive-behavioral therapy.
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Table 7. Differences in parent perception ratings based on parent’s education
Degree
(n = 34)

No degree
(n = 12)

Mann-Whitney U Test

Median

Median

U

z

p

Treatment Type

Perception Type

ABA

Acceptability

5.00

9.50

273.0

1.774

.076

Effectiveness

5.00

6.00

273.0

1.751

.080

Willingness

5.00

7.50

267.0

1.601

.109

Acceptability

8.00

10.00

196.5

-0.200

.841

Effectiveness

5.00

5.00

188.0

-0.409

.683

Willingness

8.00

10.00

252.5

1.279

.201

Acceptability

5.00

6.00

199.5

-0.115

.909

Effectiveness

5.00

6.00

214.0

0.253

.801

Willingness

5.00

6.50

210.5

0.168

.867

Acceptability

7.50

5.00

165.5

-1.004

.316

Effectiveness

5.00

5.00

197.0

-0.182

.855

Willingness

7.50

6.00

192.5

-0.293

.769

CBT

Medication

Alternative Interventions

*p ≤ .05; Abbreviations: ABA, applied behavioral analysis; CBT, cognitive-behavioral therapy.
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Table 8. Associations between parent perception ratings and clinical variables
1

2

3

4

5

1. SCAS-P Total

-

2. CGI-S Anxiety

.27

-

3. CGI-S ASD

.05

.41**

-

4. ABA acceptability

-.22

.02

.02

-

5. ABA willingness

.03

.03

.19

.74**

-

6. ABA effectiveness

-.01

.08

.16

.67**

.90**

6

7

8

9

10

11

12

13

14

-

7. CBT acceptability
-.03
.05
.18
.28
.32*
.20
8. CBT willingness
.12
.05
.26
.27
.21
.14
.60**
9. CBT effectiveness
-.03
-.06
.16
.20
.33*
.27
.54**
.71**
10. Medication acceptability
-.04
-.02
.03
-.07
-.17
-.11
.25
.37*
.17
11. Medication willingness
-.09
-.03
.04
-.15
-.22
-.11
.09
.22
.10
.90**
12. Medication effectiveness
-.18
-.03
-.09
-.02
-.15
-.05
.03
.25
.16
.70**
.77**
13. Alt. Intervention acceptability
-.18
.02
.07
.22
.06
.01
.18
.15
.14
.24
.14
.08
14. Alt. Intervention willingness
.04
.13
.14
.10
.12
.09
.05
.10
.17
.08
-.02
-.04
.74**
15. Alt. Intervention effectiveness
-.09
-.14
-.07
.17
.15
.19
-.01
.03
.12
.11
.05
.13
.61**
.71**
*p< .05, **p <.01
Abbreviations: SCAS-P, Spencer Childhood Anxiety Scale-Parent version; CGI-S, Clinical Global Impression Scale-Severity; ABA, applied behavioral analysis; CBT, cognitivebehavioral therapy, Alt. Intervention, alternative interventions.
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Table 9. Differences in parent perception ratings based on child’s treatment history
History of ABA
(n =23)

No history of ABA
(n=12)

Mann-Whitney U Test

Median

Median

U

z

p

Treatment Type

Perception Type

ABA

Acceptability

9.00

5.00

365.0

2.270

.023*

Effectiveness

7.00

4.00

393.5

2.876

.004**

Willingness

8.00

5.00

362.5

2.188

.029*

History of CBT
(n = 19)

No history of CBT
(n = 27)

Median

Median

U

z

p

Acceptability

9.00

8.00

265.0

0.203

.839

Effectiveness

5.00

5.00

298.5

0.957

.338

Willingness

10.00

6.00

326.0

1.635

.102

History of Medication
(n =28)

No history of Medication
(n = 18)

Median

Median

U

z

p

Acceptability

8.00

5.00

366.5

2.622

.009**

Effectiveness

7.00

3.00

377.0

2.842

.004**

Willingness

10.00

3.00

416.0

3.815

.000**

History of Specialized Diets
(n = 23)

No history of Specialized Diets
(n = 23)

Median

Median

U

z

p

Alternative Interventions Acceptability

8.00

5.00

349.5

1.946

.052

Effectiveness

5.00

5.00

361.5

2.217

.027*

Willingness

8.00

7.00

338.0

1.645

.100

CBT

Medication

*p< .05, **p <.01;
Abbreviations: ABA, applied behavioral analysis; CBT, cognitive-behavioral therapy.
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ABA

Median = 6.00
IQR = 4.75-10.00

CBT

Median = 8.50
IQR = 5.00-10.00

Medication

Median = 5.00
IQR = 3.00-10.00

Alt. Intervention

Median = 7.00
IQR = 5.00-10.00
0%

20%

0 'Not at all Acceptable'

40%
1

2

3

60%
4

5

6

80%
7

8

9

100%
10 'Completely Acceptable'

Figure 1. Parent acceptability ratings across treatment types
Abbreviations: ABA, applied behavioral analysis; CBT, cognitive-behavioral therapy; Alt.
intervention, alternative intervention; IQR, interquartile range.

ABA

Median = 5.00
IQR = 1.00-10.00

CBT

Median = 5.00
IQR = 4.75-8.00

Medication

Median = 5.00
IQR = 2.00-8.00

Alt. Intervention

Median = 5.00
IQR = 5.00-7.00
0%

20%

0 'Not at all Effective'

40%
1

2

3

60%
4

5

6

80%
7

8

9

100%
10 'Completely Effective'

Figure 2. Parent effectiveness ratings across treatment types
Abbreviations: ABA, applied behavioral analysis; CBT, cognitive-behavioral therapy; Alt.
intervention, alternative intervention; IQR, interquartile range.
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ABA

Median = 5.00
IQR = 2.00-10.00

CBT

Median = 8.50
IQR = 5.00-10.00

Medication

Median = 5.00
IQR = 3.00-10.00
Median = 7.00
IQR = 5.00-9.25

Alt. Intervention
0%

20%

40%

0 'Not at all Willing'

1

2

3

60%
4

5

6

80%
7

8

9

100%
10 'Completely Willing'

Figure 3. Parent willingness ratings across treatment types
Abbreviations: ABA, applied behavioral analysis; CBT, cognitive-behavioral therapy; Alt.
intervention, alternative intervention; IQR, interquartile range.

Personal experience

Median = 8.00
IQR = 0.00-10.00

Expected cost/coverage

Median = 7.00
IQR = 4.00-10.00

Availability of treatment

Median = 8.00
IQR = 5.00-10.00

Expected child engagement

Median = 7.50
IQR = 4.00-10.00

Understanding of treatment

Median = 8.00
IQR = 5.00-10.00
Median = 5.00
IQR = 1.00-9.00

Other practical barriers
0%

0 'Did not influence'

20%

1

2

3

40%

4

5 'moderately'

60%

6

Figure 4. Factors that influence parent perceptions of ABA
Abbreviations: IQR, interquartile range.
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80%

7

8

9

100%

10 'Completely influenced'

Median = 7.00
IQR = 0.00-10.00

Personal experience
Expected cost/coverage

Median = 5.00
IQR = 1.00-8.00

Availability of treatment

Median = 6.50
IQR = 5.00-10.00

Expected child engagement

Median = 6.00
IQR = 5.00-10.00

Understanding of treatment

Median = 8.00
IQR = 5.00-10.00
Median = 5.00
IQR = 2.75-7.25

Other practical barriers
0%
0 'Did not influence'

20%

1

2

3

40%
4

60%

5 'moderately'

6

80%
7

8

100%

9

10 'Completely influenced'

Figure 5. Factors that influence parent perceptions of CBT
Abbreviations: IQR, interquartile range.

Median = 10.00
IQR = 4.50-10.00

Personal experience
Expected cost/coverage

Median = 5.00
IQR = 0.00-7.25

Availability of treatment

Median = 5.00
IQR = 0.00-9.25

Expected child engagement

Median = 5.00
IQR = 1.75-10.00

Understanding of treatment

Median = 8.00
IQR = 5.00-10.00
Median = 2.00
IQR = 0.00-8.00

Other practical barriers
0%
0 'Did not influence'

20%
1

2

3

40%
4

60%

5 'moderately'

6

80%
7

8

Figure 6. Factors that influence parent perceptions of medication
Abbreviations: IQR, interquartile range.
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100%
9

10 'Completely influenced'

Personal experience

Median = 5.00
IQR = 0.00-9.25

Expected cost/coverage

Median = 5.00
IQR = 0.75-8.25

Availability of treatment

Median = 5.00
IQR = 3.00-8.00

Expected child engagement

Median = 5.00
IQR = 3.00-9.25

Understanding of treatment

Median = 7.00
IQR = 4.50-10.00
Median = 5.00
IQR = 0.00-7.00

Other practical barriers
0%
0 'Did not influence'

1

20%
2

3

40%
4

5 'moderately'

60%

80%

6

7

8

9

100%
10 'Completely influenced'

Figure 7. Factors that influence parent perceptions of alternative interventions
Abbreviations: IQR, interquartile range.

ABA

CBT

Medication

Alt. Intervention

18
16
14
Frequency

12
10
8
6
4
2
0
Rank of 1

Rank of 2

Rank of 3

Most Preferred

Rank of 4
Least Preferred

Preference Ranks

Figure 8. Parent rankings of preference for presented treatment types
Abbreviations: ABA, applied behavioral analysis; CBT, cognitive-behavioral therapy; Alt.
Intervention, alternative interventions.
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ABA
CBT
Medication
Social Skills Training
Speech Therapy
Occupational Therapy
Parent-Child Interaction Therapy
Play Therapy
Specialized Diet
Specialized School Services
0%
Very Dissatisfied

10%

Dissatisfied

20%

30%

40%

50%

Neither Dissatisfied nor Satisfied

60%

70%
Satisfied

80%

90%

Very Satisfied

Figure 9. Parent satisfaction with past treatments/services utilized for child’s needs
Abbreviations: ABA, applied behavioral analysis; CBT, cognitive-behavioral therapy.
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100%

DISCUSSION
The present study is the first to examine the perspectives and preferences of parents for
the treatment of anxiety in their children with autism spectrum disorder. Four treatments for
anxiety (i.e., applied behavioral analysis, cognitive-behavioral therapy, medication, and
alternative interventions) were briefly described and parents provided their perceptions on each
type in terms of perceived acceptability, effectiveness, and their willingness to use for their child.
Parents also indicated which of the four treatment types they would most prefer for their child.
The influence of specific factors on parent perceptions of anxiety treatment were explored.
Overall, results indicated that parent perceptions were generally favorable for all four
treatment types. A majority of the sample rated each treatment as at least moderately acceptable,
effective, and were willing to use any of them to address their child’s anxiety concerns.
Significant differences in parent acceptability and willingness ratings by treatment type were also
found. Specifically, parents perceived CBT as more acceptable for any child with anxiety and
ASD, compared to medication. Parents also showed greater willingness-to-use CBT compared to
medication or ABA for addressing their child’s anxiety. Parents did not generally perceive any
treatment as more effective than another. Together, these findings are consistent with the study
hypothesis in that parents generally perceived a behavioral intervention (CBT) more favorably
than medication; although, this was not the case for the other behavioral intervention (ABA) nor
were parent perceptions generally more favorable for either CBT or ABA compared to
alternative interventions. Nonetheless, these results are consistent with previous studies (Brown
et al., 2007; Lewin et al., 2014), which have shown CBT (or psychotherapy) as the treatment

endorsed most acceptably and more favorable among parents and individuals with anxiety,
compared to medication.
When parents were asked to indicate the extent to which several factors (i.e., personal
experience, cost/coverage, availability, child engagement, overall understanding and other
practical barriers) influenced their perceptions regarding each treatment, a majority responded
that they were at least moderately influenced by all. Unsurprisingly, the parent’s overall
understanding of each treatment appeared to generally influence perceptions the most across
treatment types, followed by the parent’s own personal experience. These findings are consistent
with previous literature in that information is key for parents when making decisions about their
child’s care (Mak, Hiebert-Murphy, Walker, & Altman, 2014). Parents wish to be well-informed
about treatment and are understandably influenced by personal experiences and widely available
information (e.g., the internet, media). The apparent role that information has on influencing
perceptions and preferences of treatment is one that needs further examination; nonetheless, it
does suggest the underlying importance for professionals to engage with families in the decisionmaking process and ensure that parents are given access to the appropriate, evidence-based
information with which to make a decision that best fits the child’s needs. Additional
investigations on the role that other factors may have in influencing parent perceptions of
treatment are also warranted.
In terms of overall preference, medication was ranked most by parents as the ‘most
preferred’ treatment for their child above all others. CBT was ranked most by parents as the
second choice, followed by alternative interventions as third, and finally, ABA as the ‘least
preferred’ treatment. Interestingly, these results appear to contradict other study findings, which
showed parents generally perceive CBT as the more acceptable treatment option, and are more
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willing-to-use, over medication. Yet, it does seem possible that some variability in what parents
find most preferable for their child’s treatment can be expected, given that perception ratings for
all four treatments were at least moderately favorable and seen as equally effective. Of course,
there may be additional factors that were not specifically examined in the study to explain an
overall parent preference for medication. One possibility is that parents may view medications as
the least demanding of the four options in regard to cost, investment, and/or management—
which could influence an overall preference for medication above CBT (or other treatments). It
should also be noted that ABA was ranked most by parents as the ‘least preferred’ treatment,
which was quite surprising. Past literature has commented on ABA to be associated with some
controversy or misconceptions, regarding treatment as too rigid, or dogmatic (Boutot & Hume,
2012; Schoen, 2003; Simpson, 2001). Therefore, it is possible that compared to other behavioral
interventions (e.g., CBT), some parents may have increased reservations about using ABA for
their child’s needs, despite generally favorable perceptions about the overall treatment. However,
parent perceptions of ABA warrant further exploration— especially with regard to factors that
may drive a choice to prefer ABA least for a child with ASD and anxiety.
In the present study, parent perceptions of treatment were further examined to assess
potential relationships with demographic and clinical characteristics of the sample. Results
indicated that parent perceptions across the four treatment types did not differ based on child
gender, race/ethnicity, or parent education. Contrary to study hypotheses, results also indicated
no associations between parent perceptions across treatments and anxiety severity or ASD
severity. Parental perceptions of ABA did differ by child age, but not for any of the other
treatments. Specifically, parents with younger children (≤12 years old) were found to generally
perceive ABA as more acceptable, effective, and were more willing to use for their child,
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compared to parents with older children (≥ 13 years old). On the one hand, this particular finding
does concur with the recognized view of ABA as an early intervention approach for autism,
suitable for very young children (CDC, 2019). On the other hand, the fact that parental
perceptions for medication did not differ based on child’s age does contradict previous studies
(Brown et al., 2007; Goin-Kochel et al., 2007), as well as study hypotheses. Parents of children
with ASD or anxiety have shown a tendency towards perceiving medications as a more favorable
choice for older children, compared to younger children (Brown et al., 2007; Goin-Kochel et al.,
2007)— likely out of concern that medication-use at a younger age could have effects on
development. It is notable that parents of the present sample are generally amenable towards
medication, regardless of age. As such, future studies are also encouraged to examine this
finding further and to investigate the extent to which other factors drive parent perceptions and
preferences for treatment.
Finally, differences in parental perceptions based on child treatment history were
assessed and found to vary across the four treatment types. As hypothesized, parents whose child
had a history of medication use did generally perceive medications for anxiety more favorably
than those without history of medication-use. This finding is consistent with previous literature
(Brown et al., 2007), which postulates that a past experience with medication may minimize
parent concerns surrounding the potentially negative side effects of treatment. A majority of the
parents who noted use of medications for their child in the past also reported neutral-to-positive
satisfaction with that treatment, which may account for the observed difference as well. Parent
perceptions regarding the behavioral interventions showed mixed results based on past
treatment-use. Consistent with findings in parents of anxious children (Brown et al., 2007),
perceptions of CBT were generally favorable and unrelated with past experience. Conversely,

34

parent perceptions of ABA were found to be more favorable among those with a history of use in
their child, compared to those who had never used ABA. One could speculate that parents
without experience of ABA may hold some reservations about the treatment approach— which,
in turn, may explain the observed difference; however, this cannot be confirmed by the results of
the present study and should be examined further.
There are several limitations that should be acknowledged when interpreting the present
findings. First, this study consisted of a relatively small sample size (N=46), which limited
statistical power for multi-group comparisons and did not allow more complex multivariate
models predicting treatment preferences. In addition, the majority of parents included in the
study were mothers (95.7%), which paired with a small sample, limits the extent to which
findings are generalizable to other parents of children with ASD and anxiety. Second, although
the development of the four treatment descriptions were based on previous literature and
reviewed by experts in the field, we cannot discount that parent’s perceptions of each treatment
may have been influenced by the type of information provided. The four treatment descriptions
were purposely kept brief, in an attempt to minimize burden and reduce potential biases across
treatment types. Finally, all data collected in this study relied entirely on parent-report, which
restricts the ability to confirm any information collected, such as the child’s anxiety severity,
ASD diagnosis, or treatment history. With these limitations in mind, the present study should be
considered preliminary in nature and future studies are encouraged to expand on findings, in
order to better understand parent perspectives and treatment preferences for ASD and anxiety.
Nevertheless, findings from the current study provide novel and useful insights into the
perceptions and preferences of parents for the treatment of anxiety in their children with ASD. In
general, the data suggests that ABA, CBT, medications, and alternative interventions are all
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treatment approaches that parents seem to consider favorably for their child, regardless of
demographic or clinical characteristics (e.g., gender, race/ethnicity, anxiety severity). CBT for
anxiety appeared as the more acceptable treatment option among parents, compared to
medications. Parents also seemed more willing-to-use CBT above medications for their child
with ASD. Nonetheless, parents overall tended to prefer medications most for their child, with
perceptions toward medications seeming to improve when considered for older children (≥13
years old) or those with experience of use. ABA tended to be preferred least by parents of the
four treatment options presented; yet, perceptions became generally more favorable when
considered for younger children and those with a history of use. Several identified factors were
shown to influence parent perceptions to at least a moderate degree; however, additional
investigations into the potential factors that affect perceptions and preferences are needed.
Garnering a clearer understanding of parents’ preferences, and the factors that drive decisionmaking of treatment for anxiety and ASD, can have significant implications in clinical care. With
such information, providers could be better-positioned to guide treatment recommendations in a
manner that would improve family engagement, treatment adherence, and outcomes. Efforts are
needed to further examine this topic of research in order to improve the utilization of appropriate
treatments/services and ensure quality care for individuals with ASD and anxiety.
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APPENDICES

Appendix A: Perceptions of Anxiety Treatment Scale
Applied Behavioral Analysis (ABA)
ABA aims to increase behaviors that are helpful for the child, while also reducing the behaviors
that are problematic and/or affect learning. In sessions, a stimulus will often be presented to
prompt a target behavior in the child. A consequence will then be provided to either increase the
frequency of the desired behavior (e.g., through praise/reward) or decrease the frequency of
problematic behaviors (e.g., through an absence of praise/reward).
Recommended Duration/Course of Treatment
An ABA-certified professional will typically meet one-on-one with child for as much as 40 hours
per week. The course of treatment can last several months or up to three years, depending on the
needs of the child.
Typical Coverage/Cost of Treatment
Some insurance plans may cover at least part of the cost of ABA. Coverage requirements vary by
state and may only cover the child up to a certain age. Out-of-pocket costs for treatment could be
about $120 per hour.
Potential Advantages
(a) Effective for reducing problem behaviors and increasing appropriate skills in children
with ASD.
(b) Can be tailored to fit the specific needs and skills of the child (e.g., suitable for children
with a range of IQs and levels of functions).
(c) Can help improve communication skills and intellectual abilities
Potential Disadvantages
(a) Visible gains (e.g., changes in behavior) may take considerable time and effort.
(b) Child may become frustrated or upset during sessions. Tantrums or outbursts may occur.
(c) May not be as effective for reducing anxiety symptoms.
1. In general, how acceptable do you find ABA for any child with anxiety and ASD?
0
Not at all
Acceptable

1

2

3

4

5

6

7

8

9

Moderately

10
Completely
Acceptable

2. How willing would you be to use ABA to address your child’s anxiety?
0
Not at all
Willing

1

2

3

4

5

6

7

8

9

Moderately

10
Completely
Willing

3. How effective do you think using ABA would be in reducing your child’s anxiety?
0

1

2

3

4

5
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6

7

8

9

10

Not at all
Effective

Completely
Effective

Moderately

4. To what extent do the following factors influence your perceptions about ABA? Please
indicate your response using the below scale of 0 to 10 (where 0 = “does not influence my
perception at all”, 5 = “Moderately Influences”, and 10 = “completely influences my
perception”).
a. Personal experience with ABA:
0
Not at all

1

2

3

4

5
6
Moderately

7

8

9

10
Completely

b. Expected cost/coverage of ABA:
0
Not at all

1

2

3

4

5
6
Moderately

7

8

9

10
Completely

3

4

5
6
Moderately

7

8

9

10
Completely

7

8

9

10
Completely

7

8

9

10
Completely

c. Availability of ABA:
0
Not at all

1

2

d. My child’s engagement with ABA:
0
Not at all

1

2

3

4

5
6
Moderately

e. My overall understanding of ABA:
0
Not at all

1

2

3

4

5
6
Moderately

f. Other practical barriers of accessing ABA (e.g., duration, transportation, child-care):
0
Not at all

1

2

3

4

5
6
Moderately

7

8

9

10
Completely

Cognitive Behavioral Therapy (CBT)

CBT aims to modify thoughts and behaviors that bring about anxiety and/or prevent the child
from learning how to cope with anxiety. In treatment, the child will learn techniques on how to
recognize anxious thoughts, manage the anxiety, change maladaptive behaviors (e.g., avoidance),
and ultimately face their fears. In addition, parents are encouraged to be actively involved in
treatment and will also learn strategies for effectively supporting their child.
Recommended Duration/Course of Treatment
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A licensed mental health professional (e.g., psychologist) will typically meet one-on-one with
the child and parent for at least 1hour, once a week. The average course of treatment is 12-16
sessions long (e.g., 3-4 months).
Typical Coverage/Cost of Treatment
Some health insurance plans may cover at least part of the cost of CBT treatment. Out-of-pocket
costs for treatment could be between $50-300 per session, depending on the provider and
insurance status.
Potential Advantages
(a) Effective for reducing anxiety in children (with or without ASD).
(b) Can be tailored to fit the symptom needs and experiences of the child, including the
interactions between ASD-related behaviors and anxiety.
(c) Can improve social functioning and daily living skills. Techniques learned in session can
also be applied to broader life problems, either currently or in the future.
Potential Disadvantages
(a) Visible gains (e.g., reduction in anxiety symptoms) may take considerable time and
effort.
(b) Child may experience a temporary increase in anxiety as they practice situations that are
difficult for them. Children may also find it hard to face their fears.
(c) Most studies evaluating CBT have included only verbally fluent children with higherfunctioning ASD, though there is promising emerging evidence for CBT in minimally
verbal and lower functioning youth with anxiety.
1. In general, how acceptable do you find CBT for any child with anxiety and ASD?
0
Not at all
Acceptable

1

2

3

4

5

6

7

8

9

Moderately

10
Completely
Acceptable

2. How willing would you be to use CBT to address your child’s anxiety?
0
Not at all
Willing

1

2

3

4

5

6

7

8

9

Moderately

10
Completely
Willing

3. How effective do you think using CBT would be in reducing your child’s anxiety?
0
Not at all
Effective

1

2

3

4

5
Moderately

6

7

8

9

10
Completely
Effective

4. To what extent do the following factors influence your perceptions about CBT? Please
indicate your response using the below scale of 0 to 10 (where 0 = “does not influence my
perception at all”, 5 = “Moderately Influences”, and 10 = “completely influences my
perception”).
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a. Personal experience with CBT:
0
Not at all

1

2

3

4

5
6
Moderately

7

8

9

10
Completely

b. Expected cost/coverage of CBT:
0
Not at all

1

2

3

4

5
6
Moderately

7

8

9

10
Completely

3

4

5
6
Moderately

7

8

9

10
Completely

7

8

9

10
Completely

7

8

9

10
Completely

c. Availability of CBT:
0
Not at all

1

2

d. My child’s engagement with CBT:
0
Not at all

1

2

3

4

5
6
Moderately

e. My overall understanding of CBT:
0
Not at all

1

2

3

4

5
6
Moderately

f. Other practical barriers of accessing CBT (e.g., duration, transportation, child-care):
0
Not at all

1

2

3

4

5
6
Moderately

7

8

9

10
Completely

Medications
Most medications work by effecting neurotransmitters, the chemicals in the brain that affect
mood and emotions. The most commonly prescribed medications for anxiety are a type of
antidepressants known as selective serotonin reuptake inhibitors (SSRIs). A few examples of
brand names of SSRIs include Zoloft, Prozac, Paxil, Lexapro and Luvox.
Recommended Duration/Course of Treatment
A licensed psychiatrist or physician can prescribe SSRIs for the child’s anxiety, after an initial
assessment of symptoms. Regular monthly appointments will be scheduled for at least the first 6
months, to closely monitor progress and adjust dosage as needed. Appointments will become less
frequent once the medications begin to show improvement. Most doctors will typically
recommend continuing on SSRIs for up to 1 year after anxiety symptoms have diminished.
Typical Coverage/Cost of Treatment
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Out-of-pocket costs for SSRIs are typically between $8-$15 per month, depending on insurance
status. Insurance plans may also cover most of the costs of psychiatrist or physician visits. Outof-pocket costs for visits can range from $20-$300 per session, depending on provider and
insurance status.
Potential Advantages
(a) Effective for reducing anxiety symptoms in youth with or without ASD.
(b) Access to medication can often be quick and conveniently prescribed by a physician or
psychiatrist.
(c) May have lower time demands/commitments than other types of treatments
Potential Disadvantages
(a) It often takes 2 weeks or more to see any improvements in anxiety when starting a SSRI.
Thus, visible gains may take considerable time, effort, and may require multiple changes
in dosage or SSRI-type.
(b) Side effects are common and may include nausea, diarrhea, headache, insomnia,
jitteriness, or restlessness.
(c) There may be a risk of rare but serious negative consequences such as an increase in
suicidal ideation or behavioral disinhibition.
1. In general, how acceptable do you find MEDICATIONS for any child with anxiety and
ASD?
0
Not at all
Acceptable

1

2

3

4

5

6

7

8

9

Moderately

10
Completely
Acceptable

2. How willing would you be to use MEDICATIONS to address your child’s anxiety?
0
Not at all
Willing

1

2

3

4

5

6

7

8

9

Moderately

10
Completely
Willing

3. How effective do you think using MEDICATIONS would be in reducing your child’s
anxiety?
0
Not at all
Effective

1

2

3

4

5
Moderately

6

7

8

9

10
Completely
Effective

4. To what extent do the following factors influence your perceptions about
MEDICATIONS? Please indicate your response using the below scale of 0 to 10 (where 0 =
“does not influence my perception at all”, 5 = “Moderately Influences”, and 10 =
“completely influences my perception”).
a. Personal experience with MEDICATIONS:
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0
Not at all

1

2

3

4

5
6
Moderately

7

8

9

10
Completely

5
6
Moderately

7

8

9

10
Completely

5
6
Moderately

7

8

9

10
Completely

7

8

9

10
Completely

7

8

9

10
Completely

b. Expected cost/coverage of MEDICATIONS:
0
Not at all

1

2

3

4

c. Availability of MEDICATIONS:
0
Not at all

1

2

3

4

d. My child’s engagement with MEDICATIONS:
0
Not at all

1

2

3

4

5
6
Moderately

e. My overall understanding of MEDICATIONS:
0
Not at all

1

2

3

4

5
6
Moderately

f. Other practical barriers of accessing MEDICATIONS (e.g., duration, transportation,
child-care):
0
Not at all

1

2

3

4

5
6
Moderately

7

8

9

10
Completely

Alternative (Alt.) Interventions
There are a wide range of alternative interventions that may be used with the intent of reducing
anxiety symptoms in youth with ASD. For example, dietary restrictions involving glutenfree/wheat-free diet, casein-free/dairy free diet, or foods that may impact serotonin. Other
examples of alternative interventions include nutritional supplements and herbs, exercise,
breathing/relaxation techniques, or the use of self-help books.
Recommended Duration/Course of Treatment
The duration of an alternative intervention will depend on the type of the intervention and
perceived success of the intervention. For example, it may be recommended to use specific diets
and nutritional supplements for many months before results are expected. In contrast,
breathing/relaxation techniques and tools from self-help books may be used for shorter periods
of time.
Typical Coverage/Cost of Treatment
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Most alternative interventions are paid out-of-pocket. Costs will vary depending on the specific
interventions used (e.g., price of dietary food, books, and supplements).
Potential Advantages
(a) Can be implemented in a wider range of settings (e.g., home, school).
(b) Offer flexibility in terms of effort required, cost, and time commitment.
(c) Can improve other areas of life (e.g., exercise promotes health)
Potential Disadvantages
(a) Limited evidence for use of most alternative interventions, appears to be less effective
than other treatment options already covered
(b) Requires self-motivation to maintain
(c) Usually does not have the support of a highly trained professional to guide and tailor
treatment
1. In general, how acceptable do you find ALT. INTERVENTIONS for any child with
anxiety and ASD?
0
Not at all
Acceptable

1

2

3

4

5

6

7

8

9

Moderately

10
Completely
Acceptable

2. How willing would you be to use ALT. INTERVENTIONS to address your child’s
anxiety?
0
Not at all
Willing

1

2

3

4

5

6

7

8

9

Moderately

10
Completely
Willing

3. How effective do you think using ALT. INTERVENTIONS would be in reducing your
child’s anxiety?
0
Not at all
Effective

1

2

3

4

5

6

7

8

9

Moderately

10
Completely
Effective

4. To what extent do the following factors influence your perceptions about ALT.
INTERVENTIONS? Please indicate your response using the below scale of 0 to 10 (where
0 = “does not influence my perception at all”, 5 = “Moderately Influences”, and 10 =
“completely influences my perception”).
a. Personal experience with ALT. INTERVENTIONS:
0
Not at all

1

2

3

4

5
6
Moderately

49

7

8

9

10
Completely

b. Expected cost/coverage of ALT. INTERVENTIONS:
0
Not at all

1

2

3

4

5
6
Moderately

7

8

9

10
Completely

7

8

9

10
Completely

8

9

10
Completely

8

9

10
Completely

c. Availability of ALT. INTERVENTIONS:
0
Not at all

1

2

3

4

5
6
Moderately

d. My child’s engagement with ALT. INTERVENTIONS:
0
Not at all

1

2

3

4

5
6
Moderately

7

e. My overall understanding of ALT. INTERVENTIONS:
0
Not at all

1

2

3

4

5
6
Moderately

7

f. Other practical barriers of accessing ALT. INTERVENTIONS (e.g., duration,
transportation, child-care):
0
Not at all

1

2

3

4

5
6
Moderately

7

8

9

10
Completely

From most preferred to least preferred, how would you rank each of the presented
options? Please use “1” to denote the treatment you would prefer most for your child, and “4” to
denote the treatment you would prefer least for your child.
____ ABA
____ CBT
____ Medications
____ Alternative Interventions
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Appendix B: Baylor College of Medicine IRB Approval Letter

